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Abstract
BACKGROUND: 123I-FP-CIT (DaTSCAN) SPECT studies of the nigrostriatal pathway are a valuable tool in the diagnosis of 
movement disorders. However some scans are reported as equivocal with potential adverse consequences. We investigated 
whether the use of quantification of tracer uptake within the striatum can be used to reduce the number of equivocal reports.
MATERIAL AND METHODS: BRASS software (Hermes, Sweden) was used to quantify striatal tracer uptake in DaTSCAN stud-
ies of patients referred to our institution. Scans were quantified and numerical limits were determined to distinguish between 
normal and abnormal scans. Scans were then re-reported both with, and without, the use of quantification. Number of equivocal 
reports and accuracy of reporting between the two types of reporting were compared.
RESULTS: Scan reporting using quantification led to a significant reduction in the number of equivocal reports with no sig-
nificant change in reporting accuracy.
CONCLUSION: Automated quantification of DaTSCAN studies with BRASS and the use of numerical limits can decrease the 
number of equivocal reports without affecting report accuracy.
KEY words: DaTSCAN, quantification, Parkinson’s disease, diagnosis
Nuclear Med Rev 2014; 17, 2: 65–69
Introduction
The diagnosis of idiopathic Parkinson’s disease (PD) and 
other Parkinson plus syndromes (PS) relies primarily on clinical 
assessment [1]. However in cases of diagnostic uncertainty, such 
as distinguishing PD from other causes of tremor or from Parkin-
sonian symptoms associated with neuroleptic exposure dopamine 
transporter, single photon emission computed tomography (SPECT) 
using 123I-FP-CIT (DaTSCAN) is useful and recommended [1, 2].
123I-FP-CIT (DaTSCAN) binds to pre-syxnaptic dopamine 
transporters in the striatum. If tracer uptake in either or both striata 
is reduced and increased background activity is seen, as shown in 
Figure 1, then the scan is reported as abnormal and there is a high 
probability that the patient has PD or a PS. If the uptake in the stria-
tum is normal, as shown in Figure 2, then this makes a diagnosis of 
PD or a PS unlikely [3]. In some scans, it is difficult to determine 
if tracer uptake is normal or reduced and these scans are usu-
ally reported as equivocal. Figure 3 shows a scan with reduced 
uptake on the left, but this is not obviously abnormal and may be 
reported as equivocal. Most scans are clearly normal or abnormal, 
however some are more difficult to interpret and approximately 8% 
to 9% of DaTSCANS are reported as equivocal [4 and data from 
our department]. This has the adverse consequences of delayed 
definitive diagnosis, possible delay in treatment and may also result 
in a repeat scan causing increased radiation exposure and anxiety 
to the patient and increased cost to the healthcare provider.
A number of software packages exist that allow quantification 
of uptake in the striata [5] and different methods of quantification 
exist and have been compared [6]. Quantification has been shown 
to reduce interobserver variability in scan reporting [7] and to cor-
relate with visual assessment [8], however to our knowledge no 
studies have specifically studied whether quantification can reduce 
the number of scans reported as equivocal. The aim of our study 
was to determine numerical limits from the results of quantification 
that could be used to help define scans that appear equivocal 
as normal or abnormal. 
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Materials and methods
Study design and patient selection
As post mortem diagnosis is rarely available and, according to 
recent recommendations, the diagnosis of PD is still predominantly 
based on the correct identification of its clinical features [1], we used 
clinical follow up as the gold standard for disease diagnosis. We 
chose a minimum of 18 months follow up between scan and final 
diagnosis, which was taken from the most recent correspondence 
letter in the clinical notes. Our department performed 611 scans be-
tween 2006 and 2009, of these 110 had follow up greater than 
18 months. One scan was excluded from the study as correlative 
imaging showed that the patient had had a basal ganglia infarct 
which caused marked unilateral reduction in uptake, although the 
patient did not have a diagnosis consistent with PD or a PS. Mean 
follow-up period was 3.3 years and maximum was 6.7 years. 
Each of the 109 scans was re-reported by three nuclear 
medicine consultants and two non-clinical members of the nu-
clear medicine team (physicists) with little previous experience of 
DaTSCAN interpretation. The non-clinical assessors were given 
a short tutorial on DaTSCAN reporting prior to the exercise. The 
scans were re-reported in two rounds, firstly without the results of 
quantification of uptake in the striata and secondly with the re-
sults of quantification. Each round of reporting was blinded to the 
results of previous reports, clinical details and the patient diagno-
sis and the order in which the scans were reported was changed. 
The assessors were asked to report the scans as normal, abnor-
mal or equivocal. 
Scan acquisition and processing
Patients were given an intravenous injection of ~185 MBq of 
Ioflupane ([I-123] N-w-fluoropropyl-2b-carbomethoxy-3b-(4-iodo-
phenyl) nortropane/DaTSCAN (GE Healthcare)). Images were taken 
3–4 hours post-injection, using a Philips IRIX 3 headed camera, 
a 128 × 128 matrix, 30 seconds per step, 3 degrees per step, 
low energy high resolution collimator, 20% energy window and 
Figure 1. Abnormal DaTSCAN with reduced uptake in the striata, 
particularly the putamina, bilaterally and increased background activity
Figure 2. Normal DaTSCAN with good uptake in all of the striata 
bilaterally and normal background activity
Figure 3. A scan that might be reported as equivocal
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magnification × 2. Scans were processed on a Philips Odyssey, 
re-constructed iteratively (OS ML-EM-all) and post-filtered with 
a low pass Butterworth filter of order 4 and a cut-off frequency of 
0.3 cycles/2 pixels.
Scan quantification
The Brain Registration & Analysis Software Suite (BRASS™, 
HERMES Medical, Sweden) was used to quantify tracer uptake in 
the putamina and caudate nuclei [9]. This software has been shown 
to provide consistent results independent of operator variability [10]. 
BRASS fits the patient data to a pre-existing template containing 
a number of volumes of interest (VOIs) and calculates the caudate 
and putamen uptake ratios (CUR and PUR respectively),
where C, P and B are the average counts per voxel in the cau-
date nucleus, putamen and background regions, respectively. The 
background region is a reference volume within the occipital lobe.
The PUR and CUR in the striatum bilaterally in normal and ab-
normal scans were compared. Minimum CUR and PUR (CURmin, 
PURmin) were determined above which all normal scans lay. If 
the lowest value for the CUR or PUR, on either side of a scan fell 
below CURmin or PURmin then the scan would be defined as ab-
normal. The converse was not true: if the lowest PUR or CUR fell 
above CURmin or PURmin, the scan could be normal or abnormal. 
The number of scans correctly classified as abnormal with use 
of either CURmin or PURmin was compared and the parameter 
that detected the most number of abnormal scans was used in 
the reporting exercise. 
Comparison of reporting with and without 
quantification
For each round of reporting the number of equivocal reports and 
accuracy of reporting was recorded and compared. Accuracy 
was calculated as the percentage of scans reported as normal 
or abnormal which agreed with clinical follow up (scans reported 
as equivocal were excluded from the calculation). Accuracy was cal-
culated so that if the use of quantification resulted in less scans be-
ing reported as equivocal, then we could determine if the decision 
about whether the scan was normal or abnormal was actually 
correct. Because CURmin and PURmin were determined, and then 
used, on the same population of scans it was not appropriate to 
compare accuracy of reporting between the two rounds as an in-
dependent result. 
Results
109 patients were included in the study. There were 59 men and 
50 women; mean age was 68 years. 77% (n = 84) of patients were 
diagnosed (on clinical follow up) with PD or a PS, 33% (n = 25) of 
patients were diagnosed with a range of other disorders including 
essential tremor, vascular and drug induced parkinsonism.
Figure 4 shows the uptake ratios in the putamen and caudate 
nucleus in normal and abnormal scans. The CURmin or PURmin for 
which all normal scans were equal to or lay above was 1.43 and 
1.41 respectively. Rather than use 1.42 and 1.40 as the cut off for 
which scans lying below these values are classified as abnormal, 
we used the values of 1.37 and 1.35 to give a margin of error.
The mean caudate uptake ratio in the group with PD or PS 
is approximately 61% of that measured in the non PD/PS group. For 
the putamina this value is 37%. This greater reduction in the mean 
signal in the putamen is due to neuronal degeneration affecting 
this part of the striatum first [11].
Table 1 shows the number of abnormal scans identified by 
CURmin and PURmin CURmin did not classify any scans as abnormal 
that had not already been classified as abnormal with the use of 
PURmin. Therefore PURmin only was used in the reporting exercise. 
Tables 2A and 2B show the results of the two rounds of reporting.
Mean number of equivocal reports without quantification 
was 10.6 (SD 2.3) and with quantification was 3.6 (SD 1.7). 
Student’s t-test (two tailed, paired) showed that the number of B
BPPUR −=
B
BCCUR −= and
Figure 4. The uptake ratios for the putamina (A) and the caudate 
nuclei (B) grouped into abnormal and normal scans as determined by 
clinical follow-up
Table 1. Percentage of abnormal scans identified by CURmin or PURmin
Parameter  Percentage of abnormal scans identified (n = 84)
CURmin: 1.37 61%
PURmin: 1.35 94%
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equivocal reports, with and without quantification were significantly 
different. (p < 0.01)
Accuracy of reports without the use of quantification was 96% 
(SD 1.1%) and with the use of quantification was also 96% (SD 
1.2). Student’s t-test (two tailed, paired) showed that there was no 
significant difference in reporting accuracy with and without quan-
tification (p = 0.54).
Table 2A also shows that, without quantification, the highest 
number of equivocal reports were from the non-medical reporters. 
However, with quantification, this pattern was reversed.
Discussion
Our study demonstrates that the use of automated quantifica-
tion of DaTSCAN studies and the use of numerical limits that define 
normal scans reduces the number of equivocal reports without 
reducing reporting accuracy. This is beneficial as equivocal 
DaTSCAN studies account for approximately 8% to 9% [4, data 
from our department] of cases and the most likely consequences: 
delayed diagnosis and rescan have important repercussions on 
patient outcomes.
To our knowledge, our study is the first to investigate the added 
value of semi-quantification in decreasing the number of equivo-
cal results. Other published studies on semi-quantification have 
focused on its use in intra and inter observer variability [4, 7] and 
its association with visual assessment and clinical parameters [8].
Our study also has implications for the use of non-clinical 
reporters of DaTSCAN studies. The non-clinical reporters (physi-
cists) had similar reporting accuracy as the clinicians however 
the reduction in the number of equivocal reports with the use 
of quantification was greatest for the non-clinicians. This sug-
gests that non-medical staff can be appropriately trained to ac-
curately report DaTSCAN studies and that quantification would 
be useful for this group.
We identified three important limitations to this study. The first 
is that the parameters we used (CURmin and PURmin) were defined 
and then tested on the same population of scans. Although 
this does not affect the result that the use of quantification re-
duces the number of scans that reporters report as equivocal, it did 
mean that we could not test reporting accuracy as an independent 
variable. To address this, we intend to retest the parameters on 
a new population of scans which were not originally used to define 
the parameters. 
A second limitation is that the gold standard we used for 
diagnosis (clinical follow up) may have been influenced by the 
original report of the DaTSCAN. However the mean follow-up in 
our patient population was 39 months and the shortest follow-up 
was 18 months. We would expect an incorrect diagnosis to become 
increasingly apparent and questioned during such a long follow-up. 
A final limitation is that striatal binding ratios decline with age 
[12] and so caution would have to be used when using CURmin 
and PURmin to define normal scans in the very elderly. A more ac-
curate approach would be to define different CURmin and PURmin 
for different age groups. 
Conclusion
Automated quantification of tracer uptake in the striata and 
use of PURmin reduces the number of scans reported as equivocal 
without affecting reporting accuracy.
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